Evaluating the Therapeutic Role of Lymph Node Dissection in Variant Subtype Bladder Cancer

Area of Science:

• Urology
• Oncology
• Surgical Pathology

Background:

• Radical cystectomy (RC) with lymph node dissection (LND) is standard for urothelial carcinoma (UC).
• The impact of LND on overall survival (OS) for variant subtype bladder cancer (VBC) remains unclear.
• VBC comprises a heterogeneous group of distinct diseases requiring subtype-specific evaluation.

Purpose of the Study:

• To investigate the association between LND and OS in patients with VBC undergoing RC.
• To analyze survival outcomes across different VBC subtypes based on LND receipt.

Main Methods:

• Analysis of the National Cancer Database (2004-2020) for VBC cases treated with RC.
• Stratification of patients by VBC subtype and receipt of LND.
• Kaplan-Meier and Cox proportional hazards analyses for OS based on nodal status and LND.

Main Results:

• 30,911 VBC patients undergoing RC were analyzed.
• Pathologic nodal status (pNx) rates varied significantly across subtypes.
• LND was associated with improved median OS in squamous and adenocarcinoma VBC subtypes (p<0.001 and p=0.037, respectively).
• Cox regression confirmed LND improved OS for squamous (HR 0.50) and adenocarcinoma (HR 0.65) VBC.

Conclusions:

• The benefit of LND in VBC is subtype-dependent, highlighting heterogeneity.
• LND may not offer significant survival advantages for all VBC subtypes.
• LND is correlated with improved survival in squamous and adenocarcinoma VBC, suggesting a potential therapeutic role.